semaglutide clinical trials weight loss How Did Diabetes Medications Become Meds? Beyond Journal Club on SURMOUNT-1 Trial – Core IM Podcast Blockbuster GLP-1 Diabetes and Weight

Reduction in Pigmentation: Dark spots, melasma, and age spots can be minimized

A recommended starting amount is one to two teaspoons per day, consumed with adequate water to allow proper hydration and gel formation in your digestive tract

Not intended for human or animal consumption, therapeutic use, or any form of in-vivo application

launched July 1, 2026 through December 31, 2027 Who Faces the Greatest Need for This Coverage The groups most likely to benefit from the Medicare GLP-1 Bridge program include: Medicare Part D enrollees ages 65 and older with a body mass index of 35 or higher, or a BMI of 27 or higher combined with a qualifying condition such as cardiovascular disease or prediabetes Adults with obesity who were previously unable to afford brand-name GLP-1 medications on fixed retirement incomes People who discontinued brand-name GLP-1 treatment due to cost and are eligible to re-enter with the $50 Bridge copay Patients managing obesity-related conditions including hypertension, sleep apnea, and prediabetes, who may reduce downstream healthcare costs through weight management People who already receive GLP-1 coverage through their Part D plan for diabetes, cardiovascular disease, or sleep apnea do not qualify for the Bridge program they continue to access the drugs through their existing coverage

RF Microneedling devices must be performed under medical supervision of a physician because it is an involved procedure

No Heavy Stimulants